Acellular and Cellular Lung Model to Study Tumor Metastasis
August 19th, 2018
7K views
Here, we present a protocol for an ex vivo lung cancer model that mimics the steps of tumor progression and helps to isolate a primary tumor, circulating tumor cells, and metastatic lesions.
Overview
This article presents a protocol for an ex vivo lung cancer model that simulates tumor progression. It facilitates the isolation of primary tumors, circulating tumor cells, and metastatic lesions.
Key Study Components
Area of Science
- Oncology
- Cell Biology
- Translational Medicine
Background
- The ex vivo model allows for the study of cancer progression.
- It enables the formation of primary tumors and circulating tumor cells.
- This technique can be used to assess therapeutic efficacy.
- It provides insights into personalized therapy using patient-derived tumor cells.
Purpose of Study
- To develop a model that mimics tumor progression.
- To isolate and study different cancer cell types.
- To evaluate the effectiveness of therapeutic drugs.
Methods Used
- Utilization of a deeply anesthetized rat model.
- Preparation of the chest and abdomen for tumor implantation.
- Application of chlorhexidine for skin disinfection.
- Monitoring tumor growth and progression over time.
Main Results
- Successful formation of primary tumors and circulating tumor cells.
- Demonstrated the potential for studying metastatic lesions.
- Provided a framework for personalized cancer therapy assessment.
- Highlighted the advantages of an accelerated study timeline.
Conclusions
- The ex vivo lung cancer model is effective for studying tumor dynamics.
- This method can significantly aid in cancer research and therapy development.
- Future applications may enhance personalized treatment strategies.
Frequently Asked Questions
What is the main advantage of the ex vivo model?
It allows for the study of cancer progression in an abbreviated time frame.
Can patient-derived tumor cells be used in this model?
Yes, patient-derived tumor cells can be utilized to assess therapeutic efficacy.
What types of cancer cells can be studied?
Different types of cancer cells can be isolated and studied using this model.
How does this model contribute to personalized therapy?
It enables the assessment of therapeutic drugs on tumor cells from individual patients.
What is the initial step in the protocol?
The initial step involves using a deeply anesthetized rat for the procedure.
What is the significance of using chlorhexidine?
Chlorhexidine is used for skin disinfection to prevent infection during the procedure.
Executive Industry Relevance
This ex vivo lung model enables biopharma R&D teams to study tumor metastasis in a physiologically relevant system with controlled nutrient flow and matrix interaction. It supports mechanistic de-risking by isolating variables such as extracellular matrix composition and cellular crosstalk in tumor progression. The model provides predictive value for target validation and assay development in oncology drug discovery pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of tumor-host interactions in a natural matrix to validate metastasis-related targets.
- Operational Value: Supports functional validation of therapeutic candidates by modeling circulating tumor cell shedding and metastatic lesion formation.
Screening & Assay Development
- Scientific Value: Generates quantifiable outputs such as circulating tumor cell counts and metastatic burden for assay standardization.
- Operational Value: Provides a reproducible platform for screening compounds that inhibit tumor cell extravasation or survival in lung tissue.
Translational & Preclinical Research
- Scientific Value: Maintains disease relevance through intact vasculature and bronchus architecture, enabling biomarker correlation with histopathological outcomes.
- Operational Value: Facilitates continuity from discovery to preclinical validation by modeling key steps of the metastatic cascade.
Pipeline & Workflow Integration
The model integrates into the oncology discovery workflow from target validation through lead identification, providing intermediate phenotypes that inform go/no-go decisions prior to in vivo studies.
- Discovery Biology: Supports hypothesis testing of metastasis drivers by enabling observation of tumor cell migration and colonization in lung tissue.
- Screening: Delivers quantitative dependent variable measurements such as circulating tumor cell levels and metastatic lesion formation for compound evaluation.
- Analytics: Enables statistical analysis of tumor progression metrics to compare experimental conditions and assess therapeutic impact.
- Translational Research: Aligns with preclinical continuity by preserving lung architecture and allowing histopathological validation of tumor growth and metastasis.
- Enterprise Reuse: Can be adapted across cancer types and cell lines, supporting platform reuse in oncology discovery programs.
Operational & Enterprise Impact
- Scientific Value: Reduces mechanistic ambiguity in metastasis research by isolating tumor cells from systemic variables in a controlled ex vivo environment.
- Operational Value: Standardizes tumor progression modeling through reproducible decellularization and perfusion protocols.
- Strategic Value: Improves capital efficiency by enabling early de-risking of metastasis-targeting therapies before costly in vivo studies.
- Portfolio Impact: Supports risk-adjusted prioritization of targets based on their impact on circulating tumor cell formation and metastatic outgrowth.
Implementation Considerations
- Requires expertise in rodent surgery, perfusion techniques, and sterile tissue handling.
- Dependent on bioreactor infrastructure capable of maintaining pulsatile flow and sterile conditions.
- Necessitates standardization of cell seeding protocols and media composition across teams.
- Adaptation to human or other mammalian lung scaffolds may require optimization of decellularization parameters.
- Limited by the ex vivo nature of the model, which does not capture systemic immune or hormonal influences over extended periods.
Biopharma FAQs
Why does isolating circulating tumor cells matter for target validation?
Isolating circulating tumor cells enables quantification of tumor shedding, which serves as a functional readout for metastasis-promoting targets and therapeutic efficacy.
How does independent variable isolation fit the discovery pipeline?
By decellularizing the lung matrix, the model isolates the extracellular matrix as a defined variable, allowing teams to study its specific contribution to tumor cell invasion and survival.
What quantitative dependent variable measurements enable mechanistic de-risking?
Measurements such as circulating tumor cell counts in perfusate and metastatic lesion formation in the contralateral lung provide quantifiable, reproducible endpoints for evaluating anti-metastatic compounds.
Why do replication requirements matter for cross-functional collaboration?
Standardized perfusion pressures, decellularization times, and cell seeding densities ensure reproducibility across laboratories, enabling reliable data sharing between discovery, preclinical, and translational teams.
What statistical analysis capabilities are required before implementation?
Teams must be able to perform comparative statistical analysis of tumor burden and circulating cell levels across conditions to determine significant differences in metastatic potential or drug response.
